GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Proteina Co 468530.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

58,800

+6.91%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Proteina Co

Its shares trade on KOSDAQ under the ticker 468530.KQ. It has been listed since 29 July 2025. In the fiscal year to 31 December 2025, it reported revenue of ₩2.95bn and a net loss of ₩9.01bn. At that date it held total assets of ₩31.75bn and shareholders' equity of ₩28.37bn.

PROTEINA Co., Ltd. engages in the provision of deoxyribonucleic acid based diagnostics through its protein to protein interaction profiling technology. The company is headquartered in Seoul, Seoul. The company went IPO on 2025-07-29. The firm is mainly engaged in the provision and sale of next generation PPI biomarker development solutions, antibody design and big data generation solutions, as well as single molecule protein interaction detection (SPID) platform systems’ equipment and consumables.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
29 Jul 2025
Employees
52

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Proteina Co Ltd has a focused sector in Health Care with a specific industry in Biotechnology.
  • The company employs 52 full-time employees, indicating a small but dedicated team.
  • Proteina Co Ltd offers unique technology in protein to protein interaction profiling for diagnostics.

Weaknesses

  • The company has a recent IPO date of 2025-07-29, indicating limited market history.
  • Proteina Co Ltd is headquartered in Seoul, South Korea, which may limit global market reach.
  • The company's website is provided but no additional details about its market presence are given.

Opportunities

  • The company's focus on next generation PPI biomarker development solutions presents growth potential in biotechnology.
  • Proteina Co Ltd's SPID platform systems could expand into new markets for protein interaction detection.
  • The use of big data generation solutions aligns with current trends in health care technology.

Threats

  • The company's recent IPO may face challenges in establishing a strong market position.
  • Proteina Co Ltd's reliance on a single technology may pose risks if competitors develop better solutions.
  • The biotechnology industry is highly competitive, which could impact the company's growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.